| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/02/2003 | EP1268753A2 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 01/02/2003 | EP1268555A2 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268547A2 Methods of modulating drug clearance mechanisms by altering sxr activity |
| 01/02/2003 | EP1268543A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268537A1 Crystal structure of the (aml1 runt domain)/(cbfbeta) heterodimer and the ternary complex with dna |
| 01/02/2003 | EP1268528A2 Human genes and expression products |
| 01/02/2003 | EP1268526A2 Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 01/02/2003 | EP1268525A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
| 01/02/2003 | EP1268524A2 Binding peptides for carcinoembryonic antigen (cea) |
| 01/02/2003 | EP1268523A2 Binding compounds for cc chemokine receptor 5 and methods for identifying them |
| 01/02/2003 | EP1268521A1 Receptor-binding compounds and methods for identifying them |
| 01/02/2003 | EP1268520A2 Receptor-binding compounds and methods for identifying them |
| 01/02/2003 | EP1268519A2 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| 01/02/2003 | EP1268510A2 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268503A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 01/02/2003 | EP1268502A1 O-aryl glucoside sglt2 inhibitors and method |
| 01/02/2003 | EP1268498A1 Cardioprotective phosphonates and malonates |
| 01/02/2003 | EP1268495A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268494A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268493A1 Phosphoramidate prodrugs |
| 01/02/2003 | EP1268482A1 Pyranoindoles for treating glaucoma |
| 01/02/2003 | EP1268449A1 Substituted piperidines as melanocortin receptor agonists |
| 01/02/2003 | EP1268430A1 Chemical complex compprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 01/02/2003 | EP1268428A2 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade |
| 01/02/2003 | EP1268405A1 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents |
| 01/02/2003 | EP1268404A1 Malonamic acids and derivatives thereof as thyroid receptor ligands |
| 01/02/2003 | EP1268305A1 Infusion packet with useful and decorative elements, support member, delivery system and method |
| 01/02/2003 | EP1268000A1 Spiropiperidine derivatives as melanocortin receptor agonists |
| 01/02/2003 | EP1267954A1 Medical devices suitable for gene therapy regimens |
| 01/02/2003 | EP1267940A1 Compounds for targeting |
| 01/02/2003 | EP1267935A2 Novel treatment for eye disease |
| 01/02/2003 | EP1267934A2 A novel method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 01/02/2003 | EP1267933A2 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 01/02/2003 | EP1267932A1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails |
| 01/02/2003 | EP1267929A2 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 01/02/2003 | EP1267926A2 Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
| 01/02/2003 | EP1267925A1 Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
| 01/02/2003 | EP1267918A1 Method of treatment using ligand-immunogen conjugates |
| 01/02/2003 | EP1267916A2 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance |
| 01/02/2003 | EP1267913A2 Methods for administration of therapeutic agents on an antiangiogenic schedule |
| 01/02/2003 | EP1267910A2 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 01/02/2003 | EP1267909A1 Methods of blocking tissue destruction by autoreactive t cells |
| 01/02/2003 | EP1267908A1 Vaccine for the treatment of atherosclerosis |
| 01/02/2003 | EP1267905A2 Composition for the treatment of heart failure |
| 01/02/2003 | EP1267903A1 Methods for treating glaucoma |
| 01/02/2003 | EP1267901A1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 01/02/2003 | EP1267897A1 Treatment of congestive heart failure by pretreated autologous blood |
| 01/02/2003 | EP1267896A1 Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death |
| 01/02/2003 | EP1267890A2 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| 01/02/2003 | EP1267889A1 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| 01/02/2003 | EP1267879A2 Sustained release beadlets containing stavudine |
| 01/02/2003 | EP1267878A2 Compounds with 5-ht activity useful for controlling visual field loss |
| 01/02/2003 | EP1267875A1 Sigma receptor ligands and their medical uses |
| 01/02/2003 | EP1267874A2 Therapeutic uses of ppar mediators |
| 01/02/2003 | EP1267872A2 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 01/02/2003 | EP1267871A2 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 01/02/2003 | EP1267869A1 Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance |
| 01/02/2003 | EP1267867A1 Use of prostanoid ep4 receptor antagonists for the treatment of headache and assays for such antagonists |
| 01/02/2003 | EP1267866A2 The treatment of respiratory diseases |
| 01/02/2003 | EP1267862A2 Methods and compositions for improving sleep |
| 01/02/2003 | EP1267861A2 Composition comprising paracetamol and niflumic acid |
| 01/02/2003 | EP1267860A1 Butylnitrone containing compositions for inhibition of cancer development |
| 01/02/2003 | EP1267859A2 Treatment of psoriasis |
| 01/02/2003 | EP1267858A2 Diphenyl ketoaldehyde derivatives with anti-hiv activity |
| 01/02/2003 | EP1267857A1 Method of inhibiting the expression of inflammatory cytokines and chemokines |
| 01/02/2003 | EP1267855A2 Vasopeptidase inhibitors to treat isolated systolic hypertension |
| 01/02/2003 | EP1267853A2 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 01/02/2003 | EP1267850A2 Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| 01/02/2003 | EP1267848A1 Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer |
| 01/02/2003 | EP1267846A1 Transdermal therapeutic system for the delivery of lerisetron |
| 01/02/2003 | EP1267842A1 Method for producing a controlled-release preparation |
| 01/02/2003 | EP1267839A2 Microspheres for active embolization |
| 01/02/2003 | EP1267835A1 D and l etherlipid stereoisomers and liposomes |
| 01/02/2003 | EP1267832A1 New self emulsifying drug delivery system |
| 01/02/2003 | EP1267828A2 Pharmaceutical preparations |
| 01/02/2003 | EP1267827A2 Method for treating dry eye |
| 01/02/2003 | EP1267826A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 01/02/2003 | EP1267822A2 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light |
| 01/02/2003 | EP1267803A2 Compositions and methods for treating hair loss using c 16? - c 20? aromatic tetrahydro prostaglandins |
| 01/02/2003 | EP1267800A1 Methods of modulating hair growth |
| 01/02/2003 | EP1267765A1 Antibiotic and antifungal compositions |
| 01/02/2003 | EP1267760A2 Medical procedure |
| 01/02/2003 | EP1267639A1 Carbohydrate system and a method for providing nutriton to a diabetic |
| 01/02/2003 | EP1267622A2 Anthelmintic combinations |
| 01/02/2003 | EP1267616A1 Methods of modulating hair growth |
| 01/02/2003 | EP1083897A4 Hiv integrase inhibitors |
| 01/02/2003 | EP1052993B1 Combination of an alpha-adrenergic antagonist and a nitrogen oxide donor for treating female sexual dysfunction |
| 01/02/2003 | EP0979284B1 Reagents for vaccination which generate a cd8 t cell immune response |
| 01/02/2003 | EP0910386B1 Combinations comprising vx478, zidovudine and 1592u89 for use in the treatment of hiv |
| 01/02/2003 | EP0883401B1 At1 receptor antagonist for the stimulation of apoptosis |
| 01/02/2003 | EP0863754B1 Hydrolysis-optimized lipid emulsions and use thereof |
| 01/02/2003 | EP0806960B1 Extracts of shark cartilage, process of production and uses thereof |
| 01/02/2003 | DE20215514U1 Composition for oral ingestion, useful for treating renal insufficiency, comprises defined amounts of protein, carbohydrates, fats and minerals |
| 01/01/2003 | CN1388760A Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 01/01/2003 | CN1388758A Pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| 01/01/2003 | CN1097455C New aqueous medicament preparation for the production of propellent gas-free acrosols |
| 12/31/2002 | US6500959 Pyrrolidine derivatives and processes for preparing same |
| 12/31/2002 | US6500934 Bivalent agonists for G-protein coupled receptors |